

Mitochondrial dysfunction is an important cause of new inflammatory model of multiple sclerosis

Scientific Reports

6, 33249

DOI: [10.1038/srep33249](https://doi.org/10.1038/srep33249)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mitochondria-Division Inhibitor 1 Protects Against Amyloid- β^2 induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 147-162.	1.2	83
2	A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1309-1319.	1.4	64
3	Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?. <i>Annals of Neurology</i> , 2017, 81, 811-824.	2.8	30
4	C10ORF2 mutation associated with progressive external ophthalmoplegia and clinically isolated syndrome. <i>Acta Neurologica Belgica</i> , 2017, 117, 947-949.	0.5	9
5	Mitostasis in Neurons: Maintaining Mitochondria in an Extended Cellular Architecture. <i>Neuron</i> , 2017, 96, 651-666.	3.8	379
6	Energetic mitochondrial failing in vitiligo and possible rescue by cardiolipin. <i>Scientific Reports</i> , 2017, 7, 13663.	1.6	38
7	Mitochondrial DNA Double-Strand Breaks in Oligodendrocytes Cause Demyelination, Axonal Injury, and CNS Inflammation. <i>Journal of Neuroscience</i> , 2017, 37, 10185-10199.	1.7	34
8	Reply to the letter by Finsterer et al. concerning the paper: "Affection of immune-cells by a C10orf2 mutation manifesting as mitochondrial myopathy and transient sensory transverse syndrome" by Galassi G. et al.. <i>Acta Neurologica Belgica</i> , 2017, 117, 971-972.	0.5	0
9	Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 3863-3881.	2.4	369
10	<i>In Vivo</i> Imaging of CNS Injury and Disease. <i>Journal of Neuroscience</i> , 2017, 37, 10808-10816.	1.7	24
11	Formation and disruption of functional domains in myelinated CNS axons. <i>Neuroscience Research</i> , 2017, 116, 77-87.	1.0	21
12	Riboflavin Responsive Mitochondrial Dysfunction in Neurodegenerative Diseases. <i>Journal of Clinical Medicine</i> , 2017, 6, 52.	1.0	83
13	Excitotoxins, Mitochondrial and Redox Disturbances in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 353.	1.8	48
14	Impaired Cardiac Function in Patients with Multiple Sclerosis by Comparison with Normal Subjects. <i>Scientific Reports</i> , 2018, 8, 3300.	1.6	15
15	Neuroprotective effect of S-allyl cysteine on an experimental model of multiple sclerosis: Antioxidant effects. <i>Journal of Functional Foods</i> , 2018, 42, 281-288.	1.6	8
16	Nitric Oxide and Mitochondrial Function in Neurological Diseases. <i>Neuroscience</i> , 2018, 376, 48-71.	1.1	64
17	2- O -Carba-oleoyl cyclic phosphatidic acid induces glial proliferation through the activation of lysophosphatidic acid receptor. <i>Brain Research</i> , 2018, 1681, 44-51.	1.1	16
18	Mitochondrial Reactive Oxygen Species and Type 1 Diabetes. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1361-1372.	2.5	70

#	ARTICLE	IF	CITATIONS
19	Mitochondrial damage and "plugging" of transport selectively in myelinated, small-diameter axons are major early events in peripheral neuroinflammation. <i>Journal of Neuroinflammation</i> , 2018, 15, 61.	3.1	13
20	Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018, 39, 123-130.	1.2	25
21	Mitochondria as a therapeutic target for common pathologies. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 865-886.	21.5	508
22	Maintenance mechanisms of circuit-integrated axons. <i>Current Opinion in Neurobiology</i> , 2018, 53, 162-173.	2.0	12
23	Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis. <i>Neuropharmacology</i> , 2018, 141, 181-191.	2.0	22
24	HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy. <i>Autophagy</i> , 2018, 14, 1596-1619.	4.3	101
25	On the Neuroprotective Role of Astaxanthin: New Perspectives?. <i>Marine Drugs</i> , 2018, 16, 247.	2.2	139
26	The Axon-Myelin Unit in Development and Degenerative Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 467.	1.4	161
27	Involvement of Mitochondria in Neurodegeneration in Multiple Sclerosis. <i>Biochemistry (Moscow)</i> , 2018, 83, 813-830.	0.7	35
28	Blood Mononuclear Cell Mitochondrial Respiratory Chain Complex IV Activity is Decreased in Multiple Sclerosis Patients: Effects of I^2 -Interferon Treatment. <i>Journal of Clinical Medicine</i> , 2018, 7, 36.	1.0	21
29	A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis. <i>Brain</i> , 2019, 142, 2756-2774.	3.7	35
30	Assessment of Mitochondrial Dysfunction in Experimental Autoimmune Encephalomyelitis (EAE) Models of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4975.	1.8	14
31	On elucidation of the role of mitochondria dysfunction and oxidative stress in multiple sclerosis. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 305-317.	0.2	6
32	Surgical preparations, labeling strategies, and optical techniques for cell-resolved, in vivo imaging in the mouse spinal cord. <i>Experimental Neurology</i> , 2019, 318, 192-204.	2.0	25
33	Imaging the execution phase of neuroinflammatory disease models. <i>Experimental Neurology</i> , 2019, 320, 112968.	2.0	3
34	Targeting mitochondria to protect axons in progressive MS. <i>Neuroscience Letters</i> , 2019, 710, 134258.	1.0	14
35	Mitochondrial Dysfunction and Multiple Sclerosis. <i>Biology</i> , 2019, 8, 37.	1.3	126
36	Interplay between ER stress and autophagy: A possible mechanism in multiple sclerosis pathology. <i>Experimental and Molecular Pathology</i> , 2019, 108, 183-190.	0.9	28

#	ARTICLE	IF	CITATIONS
37	Towards a comprehensive etiopathogenetic and pathophysiological theory of multiple sclerosis. <i>International Journal of Neuroscience</i> , 2020, 130, 279-300.	0.8	11
38	Gypenosides Prevent H ₂ O ₂ -Induced Retinal Ganglion Cell Apoptosis by Concurrently Suppressing the Neuronal Oxidative Stress and Inflammatory Response. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 618-630.	1.1	20
39	Neuronal mitochondrial calcium uniporter deficiency exacerbates axonal injury and suppresses remyelination in mice subjected to experimental autoimmune encephalomyelitis. <i>Experimental Neurology</i> , 2020, 333, 113430.	2.0	5
40	Metformin as a Potential Agent in the Treatment of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5957.	1.8	31
41	Optical Coherence Tomography Angiography (OCTA) in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2020, 11, 604049.	1.1	32
42	Axonal transport dysfunction of mitochondria in traumatic brain injury: A novel therapeutic target. <i>Experimental Neurology</i> , 2020, 329, 113311.	2.0	8
43	Mn-TAT PTD-Ngb ameliorates inflammation through the elimination of damaged mitochondria and the activation of Nrf2-antioxidant signaling pathway. <i>Biochemical Pharmacology</i> , 2020, 178, 114055.	2.0	8
44	Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-19.	1.9	73
45	Anterior visual system imaging to investigate energy failure in multiple sclerosis. <i>Brain</i> , 2020, 143, 1999-2008.	3.7	14
46	NRF2 as a Therapeutic Target in Neurodegenerative Diseases. <i>ASN Neuro</i> , 2020, 12, 175909141989978.	1.5	158
47	Nimodipine Reduces Dysfunction and Demyelination in Models of Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 88, 123-136.	2.8	19
48	Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis. <i>ELife</i> , 2021, 10, .	2.8	34
49	Neuron-Oligodendrocyte Interactions in the Structure and Integrity of Axons. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 653101.	1.8	59
50	Targeting the brain lesions using peptides: A review focused on the possibility of targeted drug delivery to multiple sclerosis lesions. <i>Pharmacological Research</i> , 2021, 167, 105441.	3.1	7
51	Coenzyme Q ₁₀ and the exclusive club of diseases that show a limited response to treatment. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 151-160.	0.5	4
52	Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 681386.	2.2	12
54	Experimental autoimmune encephalomyelitis from a tissue energy perspective. <i>F1000Research</i> , 2017, 6, 1973.	0.8	8
55	Novel Approaches of Oxidative Stress Mechanisms in the Multiple Sclerosis Pathophysiology and Therapy. , 0, , 155-171.		6

#	ARTICLE	IF	CITATIONS
56	Conserved spinal cord bioenergetics in experimental autoimmune encephalomyelitis in C57BL6 mice, measured using phosphorescence oxygen analyzer. <i>Heliyon</i> , 2021, 7, e08111.	1.4	0
57	Immunopathological factors associated with disability in multiple sclerosis. <i>Noropsikiyatri Arsivi</i> , 2018, 55, S26-S30.	0.2	2
58	Polyphenolsâ€™ Role in Autoimmune and Chronic Inflammatory Diseases and the Advent of Computer-Driven Plant Therapies. , 2020, , 59-84.		2
59	The Role of Nutrition in Integrative Oncology. , 2020, , 407-436.		0
61	Neuroprotective Effects of Fingolimod in a Cellular Model of Optic Neuritis. <i>Cells</i> , 2021, 10, 2938.	1.8	4
62	Nanotechnology-Based Drug Delivery Strategies to Repair the Mitochondrial Function in Neuroinflammatory and Neurodegenerative Diseases. <i>Pharmaceutics</i> , 2021, 13, 2055.	2.0	12
63	CARD19 Interacts with Mitochondrial Contact Site and Cristae Organizing System Constituent Proteins and Regulates Cristae Morphology. <i>Cells</i> , 2022, 11, 1175.	1.8	0
64	Therapeutic opportunities for targeting cellular senescence in progressive multiple sclerosis. <i>Current Opinion in Pharmacology</i> , 2022, 63, 102184.	1.7	2
65	Integrating Lipidomics and Transcriptomics Reveals the Crosstalk Between Oxidative Stress and Neuroinflammation in Central Nervous System Demyelination. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 870957.	1.7	12
66	The differentially expressed proteins related to clinical viral encephalitis revealed by proteomics. , 2022, 8, 148-164.		2
68	Basic Leucine Zipper Protein Nuclear Factor Erythroid 2â€™related Factor 2 as a Potential Therapeutic Target in Brain Related Disorders. <i>Protein and Peptide Letters</i> , 2022, 29, 676-691.	0.4	0
69	Biochemical Discrimination of the Down Syndrome-Related Metabolic and Oxidative/Nitrosative Stress Alterations from the Physiologic Age-Related Changes through the Targeted Metabolomic Analysis of Serum. <i>Antioxidants</i> , 2022, 11, 1208.	2.2	1
70	Mitochondrial Impairment: A Common Motif in Neuropsychiatric Presentation? The Link to the Tryptophanâ€™Kynurenine Metabolic System. <i>Cells</i> , 2022, 11, 2607.	1.8	72
71	Mitochondrial diseases mimicking autoimmune diseases of the CNS and good response to steroids initially. <i>European Journal of Paediatric Neurology</i> , 2022, 41, 27-35.	0.7	2
72	Axonal response of mitochondria to demyelination and complex IV activity within demyelinated axons in experimental models of multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2023, 49, .	1.8	6
73	Neuronal deletion of MnSOD in mice leads to demyelination, inflammation and progressive paralysis that mimics phenotypes associated with progressive multiple sclerosis. <i>Redox Biology</i> , 2023, 59, 102550.	3.9	8
74	Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches. <i>Pharmaceutics</i> , 2022, 14, 2657.	2.0	12
75	Analysis of shared underlying mechanism in neurodegenerative disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	5

#	ARTICLE	IF	CITATIONS
76	Oxygen treatment reduces neurological deficits and demyelination in two animal models of multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2023, 49, .	1.8	3
78	The crocin usage in multiple sclerosis disease. , 2023, , 483-497.		0
81	TCA cycle deficiency in multiple sclerosis. <i>Nature Metabolism</i> , 0, , .	5.1	0